PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech ...

PhD Defense: Giving color to immune checkpoint inhibition’s darker side On mechanisms and management of immune-related adverse even ...

In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated ...

MiNK Therapeutics surged 730% on breakthrough testicular cancer data with agenT-797. Click here to read my analysis on INKT ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

ABBV-706 is an ADC targeting SEZ6 developed by AbbVie. It is linked to a topoisomerase 1 inhibitor (TOP1i) via a ...

Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of ...

MAIA Biotechnology enrolls first patient in expansion of phase 2 clinical trial for ateganosine in advanced non-small cell lung cancer: Chicago Friday, July 11, 2025, 12:00 Hrs [I ...

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer ...